TCR2 Therapeutics up on clinical trial collaboration with Bristol Myers

TCR2 Therapeutics

25/10/2021 12:33

** Biotech co TCR2 Therapeutic Inc's shares  TCRR.O  rise
2.8% to $6.92 premarket
    ** Co enters into a clinical trial collaboration with
Bristol Myers Squibb Co  BMY.N   urn:newsml:reuters.com:*:nGNX94DVRp
    ** TCRR will test its lead candidate gavo-cel in combination
with Bristol's approved cancer drugs Opdivo and Yervoy in a
mid-stage trial in patients with certain types of solid tumors,
including ovarian cancer
    ** TCRR is sponsoring the trial
    ** TCRR stock was down ~78.2% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))